Merck KGaA / Vertex Pharmaceuticals Incorporated

Solid Tumors with DNA Damage Response Vulnerabilities

Disease Overview

DNA damage response (DDR) inhibitors exploit synthetic lethality in tumors with defective DNA repair (e.g., ATM/BRCA mutations, replication stress phenotypes). ATR is a master regulator of replication stress; selective ATR inhibition kills cancer cells dependent on ATR-mediated S-phase checkpoint repair, particularly when paired with chemotherapy or PARP inhibitors. Biomarker development for ATR-sensitive populations has proven harder than for PARP inhibitors.

Competitive Landscape

The January 2017 deal handed Merck KGaA's EMD Serono four DDR programs—lead asset VX-970 (later berzosertib/M6620), backup VX-803 (M4344), and two preclinical DDR programs—at a stage when the ATR class was emerging as the next frontier after PARP inhibitors. VX-970 was the most clinically advanced ATR inhibitor at the time, with Phase 1 data showing partial responses in platinum-resistant solid tumors and 10 ongoing Phase 1/2 combination trials. The competitive set has since expanded to include AstraZeneca's ceralasertib (AZD6738), Bayer/Repare's camonsertib (RP-3500), and Artios' ART0380 (alnodesertib). Berzosertib's Phase 2 DDRiver SCLC 250 trial of berzosertib + topotecan in relapsed platinum-resistant SCLC delivered only a 5.5% ORR with 2.2-month median PFS, leading EMD Serono to discontinue the trial in 2022. The deal allowed Vertex to redirect capital and management focus to its cystic fibrosis CFTR-modulator franchise (Trikafta) and emerging gene-editing collaboration with CRISPR Therapeutics—a portfolio shift now widely regarded as strategically vindicated despite the eventual underperformance of the ATR programs.